-

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics today announced it will highlight new preclinical data for IAM1363, a selective and brain-penetrant inhibitor of HER2 signaling for the treatment of HER2-driven cancers, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego.

The poster presentation will showcase preclinical data illustrating how the unique binding mechanism and potent HER2 activity of IAM1363 overcomes multiple resistance mechanisms and how its strong EGFR avoidance widens the safety margin. IAM1363 potently inhibits both the wild type and mutant forms of HER2, showing over 1000-fold selectivity against EGFR due to a unique binding mode and tumor enhancement not seen with other HER2 inhibitors, leading to exceptional in vivo efficacy and tolerability in various HER2-driven cancer models, including those resistant to existing HER2-targeting agents. IAM1363 is now in a Phase 1 clinical study.

Poster Presentation Details:

Presentation Title: Validation of a novel Type II HER2 inhibitor through preclinical studies across various cancer models

Abstract Number: 1980/29

Session Title: Kinase and Phosphatase Inhibitors 2

Location: Poster Section 25

Date and Time: Monday, April 8th; 9:00 – 12:30 PT

Presenter: Lana Kulyk, PhD

About Iambic Therapeutics

Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

Contacts

Jason Glashow
Glashow Strategic Communications for Iambic
Jason.Glashow@iambic.ai

Iambic Therapeutics


Release Versions

Contacts

Jason Glashow
Glashow Strategic Communications for Iambic
Jason.Glashow@iambic.ai

More News From Iambic Therapeutics

Iambic Named to CNBC’s 2025 Disruptor 50 List

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. “While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human cli...

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has completed dose escalation in IAM1363-01, its Phase 1/1b clinical trial evaluating IAM1363, a selective and brain-penetrant small molecule inhibitor of wild-type and oncogenic mutant HER2. With completion of dose escalation, Iambic is advancing two well-tolerated doses into the dose opt...

Iambic Therapeutics to Participate in June Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following June investor conferences: Jefferies Global Healthcare Conference - June 3 - 5, 2025 UBS Spring Biotech Conference - June 24, 2025 About Iambic’s AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problem...
Back to Newsroom